SOL-257

SOL-257 is an experimental gene therapy developed by SOLA Biosciences for the treatment of amyotrophic lateral sclerosis (ALS). It utilizes adeno-associated virus (AAV) to deliver a gene encoding a therapeutic fusion protein designed to selectively target and eliminate misfolded and neurotoxic TAR DNA-binding protein 43 (TDP-43) proteins, which are implicated in approximately 97% of ALS cases. The therapy leverages the JUMP70 technology platform, which uses the patient's own HSP70 chaperone system to either repair or degrade misfolded TAR DNA-binding protein 43 (TDP-43) without affecting normal TAR DNA-binding protein 43 (TDP-43) function. Preclinical studies in mouse models have shown that SOL-257 can delay disease progression, improve survival, and alleviate motor deficits associated with ALS[1][2][3][5].